Abiopharma

🔍 Feeley Kevin (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 717 shares of Class A Common Stock (Direct)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,659.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 369 shares of Class A Common Stock at $51.74 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 35,290.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 717 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 717.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 35,290 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate 91,702 shares of Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
• F4: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on December 1, 2022. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.